Cargando…

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer

Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS: In patients with high tumor load,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaertner, Florian C., Halabi, Khalil, Ahmadzadehfar, Hojjat, Kürpig, Stefan, Eppard, Elisabeth, Kotsikopoulos, Charalambos, Liakos, Nikolaos, Bundschuh, Ralph A., Strunk, Holger, Essler, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589644/ https://www.ncbi.nlm.nih.gov/pubmed/28903405 http://dx.doi.org/10.18632/oncotarget.19049

Ejemplares similares

Biodistribution and post-therapy dosimetric analysis of [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results
por: Khawar, Ambreen, et al.
Publicado: (2019)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
por: Thomas, Lena, et al.
Publicado: (2017)

Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
por: Khurshid, Zain, et al.
Publicado: (2018)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Theranostics in nuclear medicine practice
por: Yordanova, Anna, et al.
Publicado: (2017)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with (177)Lu-PSMA
por: Moazemi, Sobhan, et al.
Publicado: (2021)

DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis—Challenges and Critical Points in Implementation into Clinical Routine
por: Meisenheimer, Michael, et al.
Publicado: (2020)

Ethanol effects on (68)Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing
por: Meisenheimer, Michael, et al.
Publicado: (2019)

Evaluating a Machine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans
por: Erle, Annette, et al.
Publicado: (2021)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Radiolabeling Strategies of Nanobodies for Imaging Applications
por: Küppers, Jim, et al.
Publicado: (2021)

Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer
por: Eppard, Elisabeth, et al.
Publicado: (2017)

It is time to move forward into the era of Theranostics
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

Decision-support for treatment with (177)Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters
por: Moazemi, Sobhan, et al.
Publicado: (2021)

[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
por: Yordanova, Anna, et al.
Publicado: (2017)

Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy
por: Moazemi, Sobhan, et al.
Publicado: (2020)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

Theranostic Advances in Breast Cancer in Nuclear Medicine
por: Vahidfar, Nasim, et al.
Publicado: (2021)

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases
por: Mayer, Karin, et al.
Publicado: (2020)

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies
por: Vahidfar, Nasim, et al.
Publicado: (2022)

The effect of eating on the uptake of PSMA ligands in the salivary glands
por: Mohan, V., et al.
Publicado: (2021)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men—study protocol for a randomized trial
por: Krausewitz, P., et al.
Publicado: (2023)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay
por: Jafari, Esmail, et al.
Publicado: (2020)

Effect of Endobronchial Valve Therapy on Pulmonary Perfusion and Ventilation Distribution
por: Pizarro, Carmen, et al.
Publicado: (2015)

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy
por: Sraieb, Miriam, et al.
Publicado: (2020)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
por: Mohan, V., et al.
Publicado: (2021)

Diagnosis of peri-prosthetic loosening of total hip and knee arthroplasty using (18)F-Fluoride PET/CT
por: Koob, Sebastian, et al.
Publicado: (2019)

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
por: Huang, Steve S., et al.
Publicado: (2017)

Diagnostic accuracy of [(99m)Tc]Tc-Sestamibi in the assessment of thyroid nodules
por: Yordanova, Anna, et al.
Publicado: (2017)

Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons
por: Bundschuh, Ralph A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rgikm0dp7psmn0j2qe4qq0fduj